

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0004US1</b>	Application No. <b>10/567,265</b>
	Applicant <b>Norbert Zander et al.</b>		
	Filing Date <b>April 10, 2008</b>	Group Art Unit <b>1618</b>	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,001,200	01/04/77	Bonsen et al.			
	2	4,001,401	01/04/77	Bonsen et al.			
	3	4,053,590	10/11/77	Bonsen et al.			
	4	4,061,736	12/06/77	Bonsen et al.			
	5	4,925,677	05/15/90	Feijen			
	6	5,079,337	01/07/92	Leonard et al.			
	7	5,723,589	03/03/98	Miljkovic et al.			
	8	5,880,270	03/09/99	Berninger et al.			
	9	5,952,347	09/14/99	Arison et al.			
	10	6,011,008	01/04/00	Domb et al.			
	11	6,261,800	07/17/01	Nikolics et al.			
	12	6,340,746	01/22/02	Roberts et al.			
	13	6,375,846	04/23/02	Jarrett et al.			
	14	6,875,594	04/05/05	Muir et al.			
	15	7,115,576	10/03/06	Sommermeyer			
	16	7,179,617	02/20/07	DeFrees et al.			
	17	7,285,661	10/23/07	Sommermeyer et al.			
	18	2004/0043446	03/04/04	DeFrees et al.			
	19	2002/0151006	10/17/02	Muir et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	20	0 127 839	07/15/92	EP				
	21	0 218 825	04/22/87	EP				
	22	0 331 471	12/16/92	EP				
	23	0 342 557	11/23/94	EP				
	24	0 549 721	04/13/94	EP				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0004US1</b>	Application No. <b>10/567,265</b>
	Applicant <b>Norbert Zander et al.</b>		
	Filing Date <b>April 10, 2008</b>	Group Art Unit <b>1618</b>	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	25	1 064 951	01/03/01	EP				
	26	1 424 086	06/02/04	EP				
	27	1 549 246	10/19/76	GB				
	28	WO 80/02374	11/13/80	WO				
	29	WO 94/07536	04/14/94	WO				
	30	WO 00/78355	12/28/00	WO				
	31	WO 01/70272	09/27/01	WO				
	32	WO 02/20033	03/14/02	WO				
	33	WO 03/31464	04/17/03	WO				
	34	WO 03/31581	04/17/03	WO				
	35	WO 03/70772	08/28/03	WO			Abst.	
	36	WO 04/24776	03/25/04	WO				
	37	WO 04/24777	03/25/04	WO				
	38	WO 04/30701	04/15/04	WO				
	39	WO 04/33651	04/22/04	WO				
	40	WO 05/14024	02/17/05	WO				
	41	WO 05/14035	02/17/05	WO				
	42	WO 05/14050	02/17/05	WO				
	43	WO 05/14655	02/17/05	WO				
	44	WO 05/74993	08/18/05	WO				
	45	WO 05/92390	10/06/05	WO				
	46	WO 06/108052	10/12/06	WO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	47	Adamczyk and Fishpauh, "A Solid Supported Synthesis of Thiol Esters," <u>Tetrahedron Lett.</u> , 1996, 37(25):4305-4308
	48	Aly et al., "Hemophilia A due to mutations that create new N-glycosylation sites," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, 89(11):4933-4937

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0004US1</b>	Application No. <b>10/567,265</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant <b>Norbert Zander et al.</b>	
		Filing Date <b>April 10, 2008</b>	Group Art Unit <b>1618</b>
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	49	Anderson and Meister, "Inhibition of $\gamma$ -glutamyl transpeptidase and induction of glutathionuria by $\gamma$ -glutamyl amino acids," <u>Proc. Natl. Acad. Sci. USA</u> , 1986, 83:5029-5032
	50	Andersson et al., "Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma," <u>Proc. Natl. Acad. Sci. USA</u> , 1986, 83(9):2979-2983
	51	Armitage, "Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor," <u>Blood</u> , 1998, 92(12):4491-4508
	52	Axén et al., "Chemical Coupling of Peptides and Proteins to Polysaccharides by Means of Cyanogen Halides," <u>Nature</u> , 1967, 214:1302-1304
	53	Balland et al., "Characterisation of two differently processed forms of human recombinant factor IX synthesised in CHO cells transformed with a polycistronic vector," <u>Eur. J. Biochem.</u> , 1988, 172(3):565-572
	54	Bauer and Rosenberg, "Role of antithrombin III as a regulator of in vivo coagulation," <u>Semin. Hematol.</u> , 1991, 28(1):10-18
	55	Berg et al., "Engineering the proteolytic specificity of activated protein C improves its pharmacological properties," <u>Proc. Natl. Acad. Sci. USA</u> , 2003, 100(8):4423-4428
	56	Bhattacharyya et al., "Recombinant Factor VIII for Haemophilia," <u>CRIPS</u> , 2003, 4(3):2-8
	57	Bjork and Danielsson, "Antithrombin and related inhibitors of coagulation proteinases," <u>Proteinase Inhibitors</u> , Barrett and Salvesen (eds.), 1986, Chapter 17, Amsterdam, The Netherlands, Elsevier Science Publishers (Biomedical Division), pp. 489-513
	58	Boorsma et al., "Bioprocess applications of a Sindbis virus-based temperature-inducible expression system," <u>Biotechnol. Bioeng.</u> , 2002, 79(6): 602-609
	59	Carrell et al., "Human alpha 1-antitrypsin: carbohydrate attachment and sequence homology," <u>FEBS Letters</u> , 1981, 135(2):301-303
	60	Carrell et al., "Structural mobility of antithrombin and its modulation by heparin," <u>Thromb. Haemost.</u> , 1997, 78(1):516-519
	61	Carver et al., "Expression of human alpha 1 antitrypsin in transgenic sheep," <u>Cytotechnology</u> , 1992, 9(1-3):77-84
	62	Castillo et al., "Sensitive substrates for human leukocyte and porcine pancreatic elastase: a study of the merits of various chromophoric and fluorogenic leaving groups in assays for serine proteases," <u>Anal. Biochem.</u> , 1979, 99(1):53-64
	63	Cebon et al., "Granulocyte-macrophage colony stimulating factor from human lymphocytes. The effect of glycosylation on receptor binding and biological activity," <u>J. Biol. Chem.</u> , 1990, 265(8):4483-4491
	64	Cera et al., "Water-soluble polysaccharide-anthracycline conjugates: biological activity," <u>Anti-Cancer Drug Design</u> , 1992, 7(2):143-151
	65	Cervigni et al., "Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation," <u>Angewandte Chemie International Edition in English</u> , 1996, 35(11):1230-1232
	66	Chan et al., "Preparation of O-esters from the corresponding thiol esters: tert-butyl cyclohexanecarboxylate," <u>Organic Syntheses Coll.</u> , 1990, 7:87-93
	67	Chaplin and Kennedy (eds.), <u>Carbohydrate Analysis: a practical approach</u> , 1994, 2nd Edition, Chapter 1 "Monosaccharides" pp. 1-41, Chapter 2 "Oligosaccharides" pp. 42-72, Chapter 3 "Neutral Polysaccharides" pp. 73-124, Chapter 5 "Glycoproteins" pp. 175-177 and 181-293, IRL Press

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0004US1</b>	Application No. <b>10/567,265</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant <b>Norbert Zander et al.</b>	
		Filing Date <b>April 10, 2008</b>	Group Art Unit <b>1618</b>
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	68	Chen et al., "Purification of alpha 1 proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography," <u>VoxSanguinis</u> , 1998, 74(4):232-241
	69	Choay et al., "Structural studies on a biologically active hexasaccharide obtained from heparin," <u>Ann. NY Acad. Sci.</u> , 1981, 370:644-649
	70	Choay et al., "Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity," <u>Biochem. Biophys. Res. Commun.</u> , 1983, 116(2):492-499
	71	Colman, "Production of therapeutic proteins in the milk of transgenic livestock," <u>Biochem. Soc. Symp.</u> , 1998, 63:141-147
	72	Conradt et al., "Expression of human interleukin-2 in recombinant baby hamster kidney, Ltk-, and Chinese hamster ovary cells. Structure of O-linked carbohydrate chains and their location within the polypeptide," <u>J. Biol. Chem.</u> , 1989, 264:17368-17373
	73	Corey and Clark, "A New Method for the Synthesis of 2-Pyridinethiol Carboxylic Esters," <u>Tetrahedron Lett.</u> , 1979, 2875-2878
	74	De Koning et al., "An approach to the synthesis of peptide-PNA-peptide conjugates via native ligation," <u>Tetrahedron Letters</u> , 2002, 43(45):8173-8176
	75	Denzlinger et al., "Differential activation of the endogenous leukotriene biosynthesis by two different preparations of Granulocyte-Macrophage Colony-Stimulating Factor in healthy volunteers," <u>Blood</u> , 1993, 81(8):2007-2013
	76	<u>Dictionary of Chemistry and Chemical Technology</u> , 2003, page 769 (English translation provided)
	77	Dieterich et al., "Hydroxyethyl Starch Antibodies in Humans: Incidence and Clinical Relevance," <u>Anesth. Analg.</u> , 1998, 86:1123-1126
	78	Donahue et al., "Effects of N-linked carbohydrates on the in vivo properties of human GM-CSF," <u>Cold Spring Harbor Symp. Quant. Biol.</u> , 1986, 51:685-692
	79	Franzen et al., "Structural studies on the carbohydrate portion of human antithrombin III," <u>J. Biol. Chem.</u> , 1980, 255(11):5090-5093
	80	Fujiki et al., "Studies on the disulfide bonds in human pituitary follicle-stimulating hormone," <u>Biochim. Biophys. Acta</u> , 1980, 624:428-435
	81	Goldstein and Gelb, "An alternate preparation of thioester resin linkers for solid-phase synthesis of peptide C-terminal thioacids," <u>Tetrahedron Lett.</u> , 2000, 41(16):2797-2800
	82	Goronzy et al., "T-Cell Derived Lymphokines as Regulators of Chronic Inflammation: Potential Targets for Immunomodulation," <u>Am. J. Therap.</u> , 1996, 3(2):109-114
	83	Gribben et al., "Development of antibodies to unprotected glycosylation sites on recombinant GM-CSF," <u>Lancet</u> , 1990, 335:434-437
	84	Harris et al., "Pegylation. A novel process for modifying pharmacokinetics," <u>Clin. Pharmacokinet.</u> , 2001, 40(7):539-551
	85	He et al., "A simplified system for generating recombinant adenoviruses," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95(5):2509-2514
	86	Hodges and Chan, "Locations of oligosaccharide chains in human alpha 1-protease inhibitor and oligosaccharide structures at each site," <u>Biochemistry</u> , 1982, 21(11):2805-2810
	87	Hodges et al., "Structure of the oligosaccharide chains in human alpha 1-protease inhibitor," <u>J. Biol. Chem.</u> , 1979, 254(17):8208-8212

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Norbert Zander et al.	
		Filing Date April 10, 2008	Group Art Unit 1618

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	88	Hovgaard et al., "Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF," <u>Eur. J. Clin. Inv.</u> , 1992, 22:45-49
	89	Hovinen et al., "Ethyl[2-deoxy-5-0-(4,4'-dimethoxytrityl)- $\alpha$ - and $\beta$ -D-erythro-pentofuranosyl] acetates as versatile intermediates in nucleic acid chemistry," <u>Nucleosides Nucleotides</u> , 1999, 18:1263-1264
	90	Iakovenko et al., "Semi-synthetic Rab proteins as tools for studying intermolecular interactions," <u>FEBS Letters</u> , 2000, 468:155-158
	91	Ingenito et al., "Solid Phase Synthesis of Peptide C-Terminal Thioesters by Fmoc/t-Bu Chemistry," <u>J. Am. Chem. Soc.</u> , 1999, 121:11369-11374
	92	Jaques et al., "N.M.R. spectroscopy and calcium binding of sialic acids: N-glycolylneuraminic acid and periodate-oxidized N-acetylneuraminic acid," <u>Carb. Res.</u> , 1980, 83:21-32
	93	Karpusas et al., "Commercial preparations of interferon beta are Betaseron (IFN beta 1b), Avonex and Rebif (IFN beta 1a)," <u>Proc. Natl. Acad. Sci. USA</u> , 1997, 94:11813-11818
	94	Kaufman et al., "Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells," <u>J. Biol. Chem.</u> , 1988, 263(13):6352-6362
	95	Kaushansky et al., "Role of carbohydrate in the function of human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Biochemistry</u> , 1987, 26:4861-4867
	96	Keene et al., "Expression of biologically active human follitropin in Chinese hamster ovary cells," <u>J. Biol. Chem.</u> , 1989, 264:4769-4775
	97	Kochendoerfer et al., "Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein," <u>Science</u> , 2003, 299(5608):884-887
	98	Kraehenbuhl et al., "Preparation and Characterization of an Immuno Electron Microscope Tracer consisting of a Heme Octa Peptide coupled to FAB," <u>J. Exp. Med.</u> , 1974, 139(1):208-223
	99	Lahiri et al., "Antithrombin-heparin cofactor: an inhibitor of plasma kallikrein," <u>Arch. Biochem. Biophys.</u> , 1976, 175:737-747
	100	Lapthorn et al., "Crystal structure of human chorionic gonadotropin," <u>Nature</u> , 1994, 369:455-461
	101	Lee et al., "Conjugation of Trypsin by Temperature-Sensitive Polymers Containing a Carbohydrate Moiety: Thermal Modulation of Enzyme Activity," <u>Biotechnol. Prog.</u> , 1998, 14:508-516
	102	Li et al., "Direct preparation of peptide thioesters using an Fmoc solid-phase method," <u>Tetrahedron Lett.</u> , 1998, 39(47):8669-8672
	103	Lin et al., "L-Cysteine as a water-soluble cation scavenger in the removal of the 2,4,6-trimethoxybenzyl group from thiols," <u>Tetrahedron Lett.</u> , 2002, 43:4531-4533
	104	Luo et al., "Controlled DNA delivery systems," <u>Pharm. Res.</u> , 1999, 16(8):1300-1308
	105	March, <u>Advanced Organic Chemistry</u> , 1992, 4th edition, John Wiley and Sons, New York, p.409
	106	Masamune et al., "A General, Selective Synthesis of Thiol Esters," <u>Can. J. Chem.</u> , 1975, 53:3693-3695
	107	Masamune et al., "Tylonolide hemiacetal, the aglycone of tylosin, and its partial synthesis," <u>J. Am. Chem. Soc.</u> , 1976, 98(24):7874-7875
	108	Masuda et al., "Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir," <u>Bioorg. Med. Chem. Lett.</u> , 2003, 13(4):669-673
	109	Mega et al., "Studies on the oligosaccharide chains of human alpha 1-protease inhibitor. I. Isolation of glycopeptides," <u>J. Biol. Chem.</u> , 1980, 255(9):4053-4056
Examiner Signature		Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Norbert Zander et al.	
		Filing Date April 10, 2008	Group Art Unit 1618

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	110	Mega et al., "Studies on the Oligosaccharide Chains of Human $\alpha$ 1-Protease Inhibitor. II. Structure of oligosaccharides," <u>J. Biol. Chem.</u> , 1980, 255(9):4057-4061
	111	Menache, "Antithrombin III: introduction," <u>Semin. Hematol.</u> , 1991, 28(1):1-2
	112	Menache et al., "Antithrombin III: physiology, deficiency, and replacement therapy," <u>Transfusion</u> , 1992, 32(6):580-588
	113	Merck Index 2006, Definition of Dimethyl Sulfoxide, Merck & Co., 14th Edition, accessed online: <a href="http://themerckindex.cambridgesoft.com/themerckindex/index.asp">http://themerckindex.cambridgesoft.com/themerckindex/index.asp</a> on Sept. 4, 2007
	114	Ming et al., "Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium," <u>J. Mol. Cell. Immunol.</u> , 1989, 4:203-211
	115	Moonen et al., "Increased biological activity of deglycosylated recombinant human granulocyte-macrophage colony-stimulating factor produced by yeast or animal cells," <u>Proc. Natl. Acad. Sci. USA</u> , 1987, 84(13):4428-4431
	116	Mori et al., "The activation of type 1 and type 2 plasminogen by type I and type II tissue plasminogen activator," <u>J. Biol. Chem.</u> , 1995, 270(7):3261-3267
	117	Mueller et al., "Recombinant Glycoprotein Product Quality in Proliferation-Controlled BHK-21 Cells," <u>Biotechnol. Bioeng.</u> , 1999, 65(5):529-536
	118	Muir et al., "Expressed protein ligation: a general method for protein engineering," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95(12):6705-6710
	119	Mukaiyama et al., "Peptide Synthesis via Oxidation-Reduction Condensation by the Use of Non-metallic Compound as a Mercaptan Scavenger," <u>Bull. Chem. Soc. Jpn.</u> , 1970, 43:1271
	120	Mumberg et al., "Regulatable promoters of <i>Saccharomyces cerevisiae</i> : comparison of transcriptional activity and their use for heterologous expression," <u>Nucl. Acids Res.</u> , 1994, 22(25):5767-5768
	121	Murano et al., "Some properties of antithrombin-III and its concentration in human plasma," <u>Thromb. Res.</u> , 1980, 18(1-2):259-262
	122	Ohta et al., "Usefulness of Glycopeptide Mapping by Liquid Chromatography/Mass Spectrometry in Comparability Assessment of Glycoprotein Products," <u>Biologicals</u> , 2002, 30(3):235-244
	123	Okamoto et al., "Purification and characterization of three forms of differently glycosylated recombinant human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Arch. Biochem. Biophys.</u> , 1991, 286(2):562-568
	124	Olson and Bjork, "Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects," <u>J. Biol. Chem.</u> , 1991, 266(10):6353-6364
	125	Olson et al., "Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement," <u>J. Biol. Chem.</u> , 1992, 267(18):12528-12538
	126	Opal et al., "Antithrombin, heparin, and heparan sulfate," <u>Crit. Care Med.</u> , 2002, 30(5):S325-S331
	127	Pelter et al., "Synthesis of Thioesters by Reactions of Carboxylic Acids with Tris-(ethylthio)borane," <u>J. Am. Chem. Soc., Perkin Trans I</u> , 1977, 1672-674
	128	Peterson, <u>The Physiological Inhibitions of Blood Coagulation and Fibrinolysis</u> , Elsevier/ North-Holland Biomedical Press 1979, p. 43
	129	Pike et al., "Heparin-dependent Modification of the Reactive Center Arginine of Antithrombin and Consequent Increase in Heparin Binding Affinity," <u>J. Biol. Chem.</u> , 1997, 272(32):19652-19655

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0004US1</b>	Application No. <b>10/567,265</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Norbert Zander et al.</b>	
		Filing Date <b>April 10, 2008</b>	Group Art Unit <b>1618</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	130	Ragnhammar et al., "Induction of anti-recombinant human Granulocyte-Macrophage Colony-Stimulating Factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients," <u>Blood</u> , 1994, 84:4078-4087
	131	Rapoport et al., "Protein transport across the eukaryotic endoplasmic reticulum and bacterial inner membranes," <u>Annu. Rev. Biochem.</u> , 1996, 65:271-303
	132	Reddy et al., "Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C," <u>Advanced Drug Delivery Reviews</u> , 2002, 54:571-586
	133	Revoltella et al., "Natural and therapy-induced anti-GM-CSF and anti-G-CSF antibodies in human serum," <u>Leukemia and Lymphoma</u> , 1997, 26:29-34
	134	Roemisch et al., "Antithrombin: a new look at the actions of a serine protease inhibitor," <u>Blood Coagul Fibrinolysis</u> , 2002, 13(8):657-670
	135	<u>Römpp Chemielexikon</u> , Thieme Verlag Stuttgart, Germany, 9th edition, 1990, Volume 9, pages 2281-2285
	136	Rosenberg, "Role of heparin and heparinlike molecules in thrombosis and atherosclerosis," <u>Fed. Proc.</u> , 1985, 44:404-409
	137	Rosenberg et al., "Antithrombin-III," <u>Rev. Hematol.</u> , 1986, 2:351-416
	138	Schlesinger, "Alphaviruses--vectors for the expression of heterologous genes," <u>Trends Biotechnol.</u> , 1993, 11(1):18-22
	139	Shin et al., "Fmoc-Based Synthesis of Peptide- $\alpha$ Thioesters: Application to the Total Chemical Synthesis of a Glycoprotein by Native Chemical Ligation," <u>J. Am. Chem. Soc.</u> , 1999, 121:11684-11689
	140	Somogyi, "Determination of reducing sugars," <u>Meth. Carb. Chem.</u> , 1962, 1:384-386
	141	Spellman et al., "Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells," <u>J. Biol. Chem.</u> , 1989, 264:14100-14111
	142	Stetsenko et al., "Efficient conjugation of peptides to oligonucleotides by native ligation," <u>J. Org. Chem.</u> , 2000, 65(16):4900-4908
	143	Stewart et al., "Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator," <u>J. Biol. Chem.</u> , 2000, 275(14):10112-10120
	144	Tebbutt, "Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL therapeutics," <u>Curr. Opin. Mol. Ther.</u> , 2000, 2(2):199-204
	145	Thim et al., "Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells," <u>Biochemistry</u> , 1988, 27:7785-7793
	146	Toole et al., "Molecular cloning of a cDNA encoding human antihemophilic factor," <u>Nature</u> , 1984, 312(5992):342-347
	147	Travis and Salvesen, "Human plasma proteinase inhibitors," <u>Ann. Rev. Biochem.</u> , 1983, 52:655-709
	148	Ubeda and Habener, "The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by caspase-3 (CPP32/YAMA) during Fas-induced apoptosis," <u>J. Biol. Chem.</u> , 1997, 272(31):19562-19568
	149	Veronese, "Peptide and protein PEGylation: a review of problems and solutions," <u>Biomaterials</u> , 2001, 22(5):405-417

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0004US1	Application No. 10/567,265
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Norbert Zander et al.	
		Filing Date April 10, 2008	Group Art Unit 1618
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	150	Wadhwa et al., "Immunogenicity of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF," <u>Clinical Cancer Research</u> , 1999, 5:1351-1361
	151	Wasley et al., "The Importance of N- and O-Linked Oligosaccharides for the Biosynthesis and In Vitro and In Vivo Biologic Activities of Erythropoietin," <u>Blood</u> , 1991, 77(12):2624-2632
	152	Watanabe et al., "A facile synthesis of carboxylic thiol esters from carboxylic acids and thiols," <u>Chem. Lett.</u> , 1976, 741-742
	153	Weisshaar et al., "NMR investigations of the N-linked oligosaccharides at individual glycosylation sites of human lutropin," <u>Eur. J. Biochem.</u> , 1991, 195:257-268
	154	Wright et al., "High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep," <u>Biotechnology NY</u> , 1991, 9:830-834
	155	Yoshitake et al., "Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)," <u>Biochemistry</u> , 1985, 24:3736-3750

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	